Futibatinib: Paving the Way to Personalized Medicine in Intrahepatic Cholangiocarcinoma
Future Oncology · 01.06.2023 · 19 (17) · 1161-1163
DOI: 10.2217/fon-2023-0318 ↗Kurz gefasst
Editorial in der Zeitschrift Future Oncology, online erschienen am 09.06.2023. Verfasst von Rita Khoury und 5 weiteren Autor:innen. Beteiligte Einrichtung: International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
“This might be the first step in a new era for cholangiocarcinoma patients, however, many questions are to be answered”Biliary tract tumors encompass various groups of cancers, including extrahepat...
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
- Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
- Department of Hematology & Oncology, Lebanese American University Medical Center-Rizk Hopsital, Beirut, 11-3288, Lebanon.
ORCID-Profile: Khalil Saleh
Zitieren
APA
Khoury, R., Chahine, C., Ibrahim, R., Khalife, N., Saleh, M., & Saleh, K. (2023). Futibatinib: Paving the Way to Personalized Medicine in Intrahepatic Cholangiocarcinoma. Future Oncology, 19(17), 1161-1163. https://doi.org/10.2217/fon-2023-0318
Vancouver
Khoury R, Chahine C, Ibrahim R, Khalife N, Saleh M, Saleh K. Futibatinib: Paving the Way to Personalized Medicine in Intrahepatic Cholangiocarcinoma. Future Oncology. 2023;19(17):1161-1163. doi:10.2217/fon-2023-0318
BibTeX
@article{Khoury2023,
author = {Khoury, Rita and Chahine, Claude and Ibrahim, Rebecca and Khalife, Nadine and Saleh, Mohammad and Saleh, Khalil},
title = {Futibatinib: Paving the Way to Personalized Medicine in Intrahepatic Cholangiocarcinoma},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {17},
pages = {1161--1163},
doi = {10.2217/fon-2023-0318}
}
EUVIMED